Skip to main content
SpringerLink
Log in

Cyclooxygenase-2 Expression in Barrett's Esophagus

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Barrett's epithelium is a recognized premalignant condition for esophageal adenocarcinoma. Nonsteroidal antiinflammatory drugs (NSAIDs) decrease the relative risk of colon cancer in humans and the esophageal tumor load in carcinogen-treated mice. Previous studies provided conflicting results for COX-2 activity in Barrett's mucosa. Pinch mucosal biopsies were collected from Barrett's and adjacent normal esophageal mucosa from 17 patients with Barrett's esophagus. Low-grade dysplasia was found in seven patients. COX-2 protein was undetectable in normal esophageal mucosa. COX-1 protein expression did not vary between normal and Barrett's epithelium. Increased COX-2 protein was detected in Barrett's epithelium in seven patients (41%) but did not differ with or without dysplasia (43% vs 40%). In conclusion, COX-2 protein is increased in 41% of patients with Barrett's epithelium compared to normal esophageal mucosa but did not differ with or without dysplasia. COX-2 induction may be an early event in the development of Barrett's esophagus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287–1289, 1991

    Google Scholar 

  2. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 104:510–513, 1993

    Google Scholar 

  3. Cameron AJ, Lomboy CT, Pera M, Carpenter HA: Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 109:1541–1546, 1995

    Google Scholar 

  4. Hamilton SR, Smith RRL, Cameron JL: Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. Hum Pathol 19:942–948, 1988

    Google Scholar 

  5. Williamson WA, Ellis FH Jr, Gibb SP, et al: Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med 151:2212–2216, 1991

    Google Scholar 

  6. McArdle JE, Lewin KJ, Randall G, Weinstein W: Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. Hum Pathol 23:479–482, 1992

    Google Scholar 

  7. Skinner DB, Walther BC, Riddell RH, Schmidt H, Jascone C, DeMeester TR: Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg 198:554–565, 1983

    Google Scholar 

  8. Hammeteman W, Tytgat GNJ, Houthoff HJ, Van Den Tweel JG: Barrett's esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology 96:1249–1256, 1989

    Google Scholar 

  9. Reid BJ, Haggitt RC, Rubin CE, Rabinovitch PS: Barrett's esophagus correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 93:1–11, 1987

    Google Scholar 

  10. Thun MJ, Namboodiri MM, Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593–1596, 1991

    Google Scholar 

  11. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr: Aspirin use and risk of fatal cancer. Cancer Res 53:1322–1327, 1993

    Google Scholar 

  12. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S: A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83:355–358, 1991

    Google Scholar 

  13. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Meir J, Colditz GA, Graham A, Willett WC, Speizer FE: Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609–614, 1995

    Google Scholar 

  14. Logan RF, Little J, Hawkin PG, Hardcastle JD: Effect of aspirin and nonsteroidal anti-inflammatory drugs on colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 307:285–289, 1993

    Google Scholar 

  15. Greenberg ER, Baron JA, Freeman DH Jr, Mandel JS, Haile R: Reduced risk of large-bowel adenomas among aspirin users. J Natl Cancer Inst 85:912–916, 1993

    Google Scholar 

  16. Giardiello FM, Hamilton SR, Crush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316, 1993

    Google Scholar 

  17. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Attali P: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635–639, 1991

    Google Scholar 

  18. Nicholls RJ, Springall RG, Gallagher P: Regression of rectal adenomas after colectomy and ileorectal anastomosis for familial adenomatous polyposis. MBJ 296:1707–1708, 1988

    Google Scholar 

  19. Rigas B, Goldman IS, Levine L: Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122:518–523, 1993

    Google Scholar 

  20. Vane J. Towards a better aspirin. Nature 367:215–216, 1994

    Google Scholar 

  21. Jones DA, Carlton DP, Mcintyre TM, Zimmerman GA, Prescott SM: Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 268:9049–9054, 1993

    Google Scholar 

  22. DuBois RN, Awad J, Morrow J, Roberts MJ, Bishop PR: Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-α and phorbol ester. J Clin Invest 93:493–498 1994

    Google Scholar 

  23. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclo-oxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183–1188, 1994

    Google Scholar 

  24. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S: Expression of prostaglandin G/H Synthase-1 and-2 protein in human colon cancer. Cancer Res 55:2556–2559, 1995

    Google Scholar 

  25. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, White RL, Prescott SM: Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect. Proc Natl Acad Sci USA 93:4816–4820, 1996

    Google Scholar 

  26. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493–501, 1995

    Google Scholar 

  27. Reddy, BS, Rao CV, Seibert K: Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 56:4566–4569, 1996

    Google Scholar 

  28. Kawamori T, Rao CV, Seibert K, Reddy BS: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58:409–412, 1998

    Google Scholar 

  29. Funkhouser, EM, Sharp GB: Aspirin and reduced risk of esophageal carcinoma. Cancer 76:1116–1119, 1995

    Google Scholar 

  30. Schreinmachers DM, Everson RB: Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 5:138–146, 1994

    Google Scholar 

  31. Rubio CA: Antitumoral activity of indomethacin on experimental esophageal tumors. JNCI 72:705–707, 1984

    Google Scholar 

  32. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ: Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 58:2929–2934, 1998

    Google Scholar 

  33. Zimmermann KC, Srbia M, Weber AA, Borchard F, Gabbert HE, Schror K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59:198–204, 1999

    Google Scholar 

  34. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Arhen C, Correa P, Hamilton SR, Morson BC, Sommers SC, Yardlet JH: Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applications. Hum Pathol 14:931–968, 1983

    Google Scholar 

  35. Williams CS, Luongo C, Radhika A, Zhang T, Lamps LW, Nanney LB, Beauchamp RD, DuBois RN: Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 111:1134–1140, 1996

    Google Scholar 

  36. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 72:1171–1177, 1993

    Google Scholar 

  37. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121:241–246, 1994

    Google Scholar 

  38. Sturmer T, Glynn RJ, Lee IM, Manson JAE, Buring JE, Hennekens CH: Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 128:713–720, 1998

    Google Scholar 

  39. Jacoby RF, Marshall DJ, Newton MA, Novakovic K, Cole CE, Lubet RA, Kelloff GJ, Verma A, Dove WF: Chemoprevention of spontaneous intestinal adenomas in the APC Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 56:710–714, 1996

    Google Scholar 

  40. Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H Stoumen AL, Pamukcu R, Ahnen DJ: Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest and p53 induction. Cancer Res 57:2452–2459, 1997

    Google Scholar 

  41. Mahmoud NN, Boolbol SK, Dannenberg AJ, Mestre JR, Bilinski RT, Martucci C, Newmark HL, Chadburn A, Bertagnolli MM: The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 19:87–91, 1998

    Google Scholar 

  42. DuBois RN, Aramandala R, Reddy BS, Entingh AJ: Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 11:1259–1262, 1996

    Google Scholar 

  43. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM: Suppression of intestinal polyposis in APCΔ716 knockout mice by inhibition of cyclooxygenase 2 (cox-2). Cell 87:803–809, 1996

    Google Scholar 

  44. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN: Inhibition of human colon cancer cel growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99:2254–2259, 1997

    Google Scholar 

  45. Shirvani V, Ouatu-Lascar R, Kaur B, Omary MB, Triadafilopoulos G: Cyclooxygenase-2 expression in Barrett's esophagus and esophageal adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 116:G1476, 1999

    Google Scholar 

Download references

Authors
  1. Hossam M. Kandil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gordon Tanner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Walter Smalley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Susan Halter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aramandala Radhika
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Raymond N. Dubois
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kandil, H.M., Tanner, G., Smalley, W. et al. Cyclooxygenase-2 Expression in Barrett's Esophagus. Dig Dis Sci 46, 785–789 (2001). https://doi.org/10.1023/A:1010700400960

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1010700400960

Search

Navigation